Switch theme
Sign up to access all valuation multiples
Double Medical Technology Inc provides services and devices in the areas of orthopedics, wound management, neurosurgery, and general surgery. It offers product related to Trauma, Spinal and joint. The business activities are carried out through China.
2004
n/a
LTM Revenue $331M
Last FY EBITDA $77.8M
$2.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Double Medical Technology has a last 12-month revenue (LTM) of $331M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Double Medical Technology achieved revenue of $296M and an EBITDA of $77.8M.
Double Medical Technology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Double Medical Technology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $331M | XXX | $296M | XXX | XXX | XXX |
| Gross Profit | $229M | XXX | $204M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $77.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 26% | XXX | XXX | XXX |
| EBIT | $69.9M | XXX | $62.3M | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| Net Profit | $60.9M | XXX | $49.5M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Double Medical Technology's stock price is CNY 38 (or $5).
Double Medical Technology has current market cap of CNY 15.5B (or $2.2B), and EV of CNY 14.7B (or $2.0B).
See Double Medical Technology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.0B | $2.2B | XXX | XXX | XXX | XXX | $0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Double Medical Technology has market cap of $2.2B and EV of $2.0B.
Double Medical Technology's trades at 6.9x EV/Revenue multiple, and 26.2x EV/EBITDA.
Equity research analysts estimate Double Medical Technology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Double Medical Technology has a P/E ratio of 35.4x.
See valuation multiples for Double Medical Technology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV (current) | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EV/Revenue | 6.2x | XXX | 6.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 26.2x | XXX | XXX | XXX |
| EV/EBIT | 29.1x | XXX | 32.7x | XXX | XXX | XXX |
| EV/Gross Profit | 8.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 35.4x | XXX | 43.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 85.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDouble Medical Technology's last 12 month revenue growth is 23%
Double Medical Technology's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Double Medical Technology's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Double Medical Technology's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Double Medical Technology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 37% | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 48% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Double Medical Technology acquired XXX companies to date.
Last acquisition by Double Medical Technology was XXXXXXXX, XXXXX XXXXX XXXXXX . Double Medical Technology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Double Medical Technology founded? | Double Medical Technology was founded in 2004. |
| Where is Double Medical Technology headquartered? | Double Medical Technology is headquartered in China. |
| Is Double Medical Technology publicy listed? | Yes, Double Medical Technology is a public company listed on SHE. |
| What is the stock symbol of Double Medical Technology? | Double Medical Technology trades under 002901 ticker. |
| When did Double Medical Technology go public? | Double Medical Technology went public in 2017. |
| Who are competitors of Double Medical Technology? | Similar companies to Double Medical Technology include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Double Medical Technology? | Double Medical Technology's current market cap is $2.2B |
| What is the current revenue of Double Medical Technology? | Double Medical Technology's last 12 months revenue is $331M. |
| What is the current revenue growth of Double Medical Technology? | Double Medical Technology revenue growth (NTM/LTM) is 23%. |
| What is the current EV/Revenue multiple of Double Medical Technology? | Current revenue multiple of Double Medical Technology is 6.2x. |
| Is Double Medical Technology profitable? | Yes, Double Medical Technology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
